California Biopharma Co. Uncovers Massive Oncology Breakthrough

1. Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
2.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Nurix Therapeutics Inc. (NRIX:NASDAQ) announced new preclinical data across its oncology pipeline on April 22, 2026. The oncology programs were presented at the American Association for Cancer Research's (AACR) 2026 annual meeting, and the presentation highlighted programs targeting pan-mutant BRAF, CBL-B, and Aurora Kinase A (AURKA). Nurix also featured a session presentation on the broader scientific progress and clinical translation of targeted protein degradation. The company hopes to offer a way to address limitations to current treatment methods, such as resistance, incomplete pathway suppression, and inability to target non-enzymatic protein functions.

"These data, together with our participation in the AACR Advances session, highlight the growing clinical and scientific validation of targeted protein degradation as a new therapeutic modality," said Arthur T. Sands, M.D., Ph.D., president and CEO of Nurix. "Across multiple programs, we are seeing consistent evidence that these therapies can drive deeper and more durable biological responses, supporting their potential to deliver meaningful benefit for patients."

The company's drugs in development include:

• NRX-0305: NRX-0305 is a potent, selective, and orally bioavailable central nervous system (CNS)-penetrant pan-mutant BRAF degrader that Nurix is exploring for use in oncology. Nurix has reported preclinical data demonstrating potent anti-tumor activity in multiple cell line-derived and patient-derived xenograft disease models representing Class 1, Class 2, and Class 3 B-RAF mutations. Anti-tumor activity was also observed in the setting of CNS disease and treatment resistance, suggesting the potential for utility across a broad range of solid tumor types.
• NX-1607: NX-1607 is an investigational first-in-class oral inhibitor of the E3 ligase Casitas B-lineage lymphoma proto-oncogene B (CBL-B) being developed for immuno-oncology indications, including a range of solid tumor types. CBL-B is a cytoplasmic E3 ubiquitin ligase that negatively regulates T cell activation, making it an attractive target for immuno-oncology and offering a novel therapeutic approach to treat solid tumors. Inhibition of CBL-B in preclinical studies reverses T cell exhaustion, alleviates tumor-induced immunosuppression, and may also exert direct antitumor effects. Nurix is evaluating NX-1607 in an ongoing Phase 1 trial in adults in a range of oncology indications. This study includes a thorough investigation of both dose and schedule in the Phase 1a portion. 
• NRX-4972: NRX-4972 is a CNS-penetrant, orally bioavailable, and highly selective degrader of Aurora A kinase (AURKA). AURKA is an oncogene frequently overexpressed in adult solid tumors, hematologic malignancies, and pediatric cancers. Several AURKA inhibitors are effective in preclinical tumor models, but this activity has failed to translate into clinical efficacy. To address the limitations of inhibitors, Nurix has designed bifunctional targeted protein degraders of AURKA that enable the removal of both enzymatic and scaffolding functions.

Nurix reported new data demonstrating that NRX-4972's targeted degradation of AURKA enables more complete biological modulation compared to inhibition alone.

Nurix Therapeutics, Inc. is an American biopharmaceutical company dedicated to the discovery, development, and commercialization of targeted protein degradation medicines, a drug design aimed at improving treatments for patients with cancer and autoimmune diseases.

The Pharma Sector in Development

In a March 26, 2026, article for Fierce Biotech, Nick Paul Taylor wrote that pharma funding had fallen from 2024 but noted that, "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024."

In contrast, J. Edward Moreno of Sherwood News reported on January 14, 2026, that, "In 2025, announced global biotech deals totaled US$228.4 billion, up from US$132.3 billion in 2024, data from Dealogic shows . . . Just two weeks into 2026, US$9.2 billion in deals have been announced."

Moreno went on to add that movement is expected in the sector: "As some of the most lucrative drugs lose exclusivity in the next few years, pharmaceutical giants are increasingly shopping around for biotechs to add to their portfolios — and they are more than happy to pay a hefty premium for the right company . . . For some Big Pharma companies, business development spending is now about equal to, or more than, research and development."

Moreno's statement could explain the drop investors are beginning to see in research and development spending at biotech and pharma companies. On March 25, 2026, BioSpace's Annalee Armstrong reported that, "R&D spending at the top 16 pharmaceutical companies declined by 3.6% overall in 2025, as many aggressively cut spending and refocused pipelines."

Many Analysts Give 'Buy' Rating

According to Factset:

• On April 22, 2026, Gil Blum of Needham gave the company a 'Buy' rating, with a price target of US$26.00.
• Also on April 22, 2026, Jeet Mukherjee of BTIG gave the company a 'Buy' rating, with a price target of US$30.00.
• On April 21, 2026, Biren Amin of Piper Sandler Companies gave the company a 'Buy' rating, with a price target of US$35.00.
• On April 9, 2026, Biran Abrahams of RBC Capital Markets gave the company a 'Buy' rating, with a price target of US$30.00.
• On April 9, 2026, Christopher Liu of Lucid Capital Markets gave the company a 'Buy' rating, with a price target of US$27.00.
• On April 8, 2026, Sudan Loganathan of Stephens Inc. gave the company a 'Buy' rating, with a price target of US$30.00.
• On April 8, 2026, Matthew Biegler of Oppenheimer gave the company a 'Buy' rating, with a price target of US$28.00.
• On April 8, 2026, Roger Song of Jeffries gave the company a 'Buy' rating, with a price target of US$41.00.
• On April 8, 2026, Stephen D. Willey of Stifel Nicolaus gave the company a 'Buy' rating, with a price target of US$34.00.
• On April 8, 2026, Derek Archila of Wells Fargo Securities gave the company a 'Buy' rating, with a price target of US$28.00.
• On April 8, 2026, Gregory Renza of Trust Securities gave the company a 'Buy' rating, with a price target of US$30.00.
• On April 8, 2026, Joseph Catanzaro of Mizuho Securities USA gave the company a 'Buy' rating, with a price target of US$30.00.

On April 24, 2026, analysts Robert Burns and Raghuram Selvaraju, Ph.D. for H.C. Wainwright & Co. reiterated their previous 'Buy' rating for Nurix and unchanged price target of US$32.00. That number represents a 92% upside from its closing price on April 24, 2026. This reiteration comes after the company's recent presentation at the American Association for Cancer Research's conference.

The analysts stated that the "... US$32.00 price target is derived from a discounted cash flow (DCF) model employing a 10% discount rate and 1.5% terminal growth rate, with a 60% probability of approval applied to NX-2127 and NX-5948, and 20% applied to NX-1607. These assumptions yield a total firm value of approximately US$3.55 billion.

Key risks include negative clinical proof-of-concept results for NX-2127, NX-5948, or NX-1607; delays in regulatory approval; weaker-than-expected commercial uptake; partnership risk if Nurix pursues a co-promotion or co-development arrangement; and medium- to long-term dilution risk."

Another Drug in the Pipeline

The company's investor presentation lists upcoming catalysts, such as completing dose escalation of its new NX-2127 drug and selecting recommended Phase 1b doses for selected indications.

Ownership & Share Information¹

Nurix Therapeutics Inc. has a market cap of US$1.72 billion, with 103.41 million shares outstanding.

The company's 52-week range is US$8.20-US$22.50.

Institutions own most of the shares at around 60%.

Management and insiders hold around 0.3%.

The rest is held by Retail.